Natalia Neparidze, MD
Hematology · New Haven, CTNPI 1649427188
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,734 of the $12,772 with a category attached, or 84.0%. Sanofi accounts for 60.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $6,570 and has fallen 79.5% since, to $1,344 in 2025.
Across 26 payments — averaging $491.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$8K
- Janssen Scientific Affairs, LLC$4K
- Seagen Inc.$455
- Johnson & Johnson$377
- E.r. Squibb & Sons, L.L.C.$125
- Adaptive Biotechnologies Corporation$112
- plus $104 from 1 others
Across 147 payments — averaging $16,135 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1.6M
- Janssen Research & Development, LLC$352K
- Genentech, Inc.$330K
- National Marrow Donor Program$31K
- Merck$27K
- Janssen Scientific Affairs, LLC$16K
- plus $15K from 2 others
What the payments were for
- Consulting fees$10,73484%
- Food & beverage$2,03816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 11 | $7,784 |
| Janssen Scientific Affairs, LLC | 2 | $3,815 |
| Seagen Inc. | 4 | $455 |
| Johnson & Johnson | 5 | $377 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Adaptive Biotechnologies Corporation | 2 | $112 |
| Pfizer | 1 | $104 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,772 in reported general payments places this provider in the 75th percentile of 24 hematology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 15 | $287,671 |
| NinlaroIxazomib Citrate | 14 | $177,335 |
| EliquisApixaban | 53 | $52,940 |
| XareltoRivaroxaban | 16 | $17,216 |
| Enoxaparin Sodium | 18 | $9,115 |
| Acyclovir | 101 | $1,146 |
| Moxifloxacin Hcl | 13 | $456 |
| Dexamethasone | 18 | $454 |
| Ondansetron OdtOndansetron | 14 | $212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $104 | $52,94053 claims |
| Johnson & JohnsonXarelto | $377 | $17,21616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 24 hematology providers in Connecticut.
Other hematology in New Haven
- Thomas DuffyNew Haven$298K
- Layla van DorenNew Haven$142K
- Nikolai PodoltsevNew Haven$123K
- Thomas PrebetNew Haven$42K
- Anish ShardaNew Haven$10K
- Lohith GowdaNew Haven$5K
- Alan LebowitzNew Haven$144
- Richard TorresNew Haven$120
- Yifei ZhangNew Haven$71
- Stephanie HaleneNew Haven$31
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.